Resmed, Inc. (RMD) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Needham & Company Upgrades ResMed (RMD) to Buy
January 23, 2015 6:25 AM ESTNeedham & Company upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $77.00 following solid Q3 results as the product cycle drove faster growth.
Analyst Mike Matson comments, "RMD's F2Q15 revenue and EPS beat consensus. RMD's new products drove faster... More
